Last reviewed · How we verify
Sodium Bicarbonate 7.5% Injection
Sodium bicarbonate acts as a systemic alkalinizing agent that increases blood pH and bicarbonate concentration to counteract metabolic acidosis.
Sodium bicarbonate acts as a systemic alkalinizing agent that increases blood pH and bicarbonate concentration to counteract metabolic acidosis. Used for Metabolic acidosis, Diabetic ketoacidosis, Lactic acidosis.
At a glance
| Generic name | Sodium Bicarbonate 7.5% Injection |
|---|---|
| Also known as | Bicarnat® arm |
| Sponsor | Hospital General "Dr. Miguel Silva" de Morelia |
| Drug class | Alkalinizing agent |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
Sodium bicarbonate dissociates in the bloodstream to provide bicarbonate ions (HCO3−), which buffer excess hydrogen ions and raise serum pH. This mechanism is used to treat metabolic acidosis from various causes including diabetic ketoacidosis, lactic acidosis, and renal failure. The 7.5% concentration provides a moderate dose suitable for intravenous administration in acute care settings.
Approved indications
- Metabolic acidosis
- Diabetic ketoacidosis
- Lactic acidosis
- Renal tubular acidosis
- Severe diarrhea-induced acidosis
Common side effects
- Hypernatremia
- Hypokalemia
- Metabolic alkalosis (with overcorrection)
- Phlebitis at injection site
- Hypocalcemia
Key clinical trials
- Efficacy of Perineural Injection With Dextrose Versus Therapy Conventional Physics in Patients With Bell's Palsy (NA)
- Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia (PHASE4)
- Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: